粒细胞集落刺激因子治疗乙型肝炎相关慢加急性肝衰竭随机对照临床研究

发布时间：2018-01-17 23:18

本文关键词：粒细胞集落刺激因子治疗乙型肝炎相关慢加急性肝衰竭随机对照临床研究　出处：《传染病信息》2016年05期 　论文类型：期刊论文

【摘要】：目的评价重组人粒细胞集落刺激因子(recombinant granulocyte-colony stimulating factor,r G-CSF)治疗乙型肝炎相关慢加急性肝衰竭(hepatitis B virus-associated acute-on-chronic liver failure,HBV-ACLF)的有效性和安全性。方法将99例ACLF患者随机分为2组,试验组49例,对照组50例。对照组给予内科综合治疗,试验组在综合治疗基础上接受r G-CSF300μg,1次/d,皮下注射,共计6针,然后减量至隔日1次,共6次,总计12针。结果生存分析表明,试验组治疗1月、3月的生存率分别为91.3%和72.9%,大于对照组的63.7%和50.0%(P0.05)。治疗期间无严重不良反应发生。结论r G-CSF能够显著提高HBV-ACLF患者的生存率,并且有较高的安全性。
[Abstract]:Objective to evaluate the recombinant granulocyte-colony stimulating factor of recombinant human granulocyte colony stimulating factor. R G-CSF in the treatment of chronic hepatitis B associated with acute liver failure. Hepatitis B virus-associated acute-on-chronic liver failure. Methods 99 patients with ACLF were randomly divided into two groups: experimental group (49 cases) and control group (50 cases). The trial group received rG-CSF 300 渭 g / d, subcutaneously for 6 doses, and then reduced to 6 times every other day for a total of 12 doses. Results Survival analysis showed that there were 12 doses of rG-CSF 300 渭 g / d in the trial group. The survival rates of the trial group on January and March were 91.3% and 72.9%, respectively. There was no serious adverse reaction during the treatment. Conclusion rG-CSF can significantly improve the survival rate of HBV-ACLF patients. And has high safety.
【作者单位】：北京大学解放军第三0二医院教学医院肝衰竭诊疗研究中心;
【基金】：北京市科技计划首都临床特色应用研究项目(Z131107002213157)
【分类号】：R512.62;R575.3
【正文快照】： 近年来,粒细胞集落刺激因子治疗肝衰竭成为临床研究热点,特别是酒精性肝衰竭和乙型肝炎相关慢加急性肝衰竭(hepatitis B virus-associated acute-on-chronic liver failure,HBV-ACLF)的随机对照临床研究显示其具有治疗作用,且安全性良好[1-2]。2014年亚太肝病协会颁布的《慢加

【相似文献】